Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery

Drug-induced liver injury: recent advances in diagnosis and risk assessment

(2017) Gerd A Kullak-Ublick et al.   GUT

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

(2016) M. Munteanu et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A two-photon fluorescent sensor revealing drug-induced liver injury via tracking γ-glutamyltranspeptidase (GGT) level in vivo

(2016) Peisheng Zhang et al.   BIOMATERIALS

Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury

(2016) Maria Mikus et al.   LIVER INTERNATIONAL

Critical comparison of elastography methods to assess chronic liver disease

(2016) Mireen Friedrich-Rust et al.   Nature Reviews Gastroenterology & Hepatology

Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1

(2015) Werner Siegmund et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

(2015) Naga Chalasani et al.   GASTROENTEROLOGY

An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards

(2015) Jérôme Boursier et al.   JOURNAL OF HEPATOLOGY

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity

(2015) Thierry Poynard et al.   BMJ Open

Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury

(2014) Mercedes Robles–Diaz et al.   GASTROENTEROLOGY

Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database

(2013) Antonios Douros et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Bad medicine: gabapentin and pregabalin

(2013) D. Spence   BMJ-British Medical Journal

Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury

(2013) Jürgen Borlak et al.   Genome Medicine

Serum proteomic profiling in patients with drug-induced liver injury

(2012) L. N. Bell et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adverse Drug Reactions to Gabapentin and Pregabalin

(2012) Régis Fuzier et al.   DRUG SAFETY

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age

(2011) Thierry Poynard et al.   BMC GASTROENTEROLOGY

Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years

(2011) Martin C. Michel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

(2011) G P Aithal et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A generic operational strategy to qualify translational safety biomarkers

(2011) Katja Matheis et al.   DRUG DISCOVERY TODAY

Correlation versus Causation? Pharmacovigilance of the Analgesic Flupirtine Exemplifies the Need for Refined Spontaneous ADR Reporting

(2011) Nora Anderson et al.   PLoS One

What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)

(2011) Helmi M’Kada et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Pathology of flupirtine-induced liver injury:

(2011) Florian Puls et al.   VIRCHOWS ARCHIV

ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure

(2010) T. Poynard et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Investigation of the in Vitro Metabolism of the Analgesic Flupirtine

(2008) K. Methling et al.   DRUG METABOLISM AND DISPOSITION

The current state of serum biomarkers of hepatotoxicity

(2007) Josef Ozer et al.   TOXICOLOGY